Stocks to watch on November 1, 2023: Bank of Baroda's head of digital lending, Akhil Handa, a techie closely associated with building the mobile banking application 'bob World', has quit
Mankind Pharma on Tuesday said its consolidated net profit increased by 21 per cent to Rs 511 crore for the second quarter ended September 30, 2023, on the back of robust performance across segments. The company had reported a net profit of Rs 422 crore in the July-September period of the last fiscal. Revenue from operations rose to Rs 2,708 crore in the period under review from Rs 2,425 crore in the year-ago period, Mankind Pharma said in a regulatory filing. "The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in future," Mankind Pharma Vice Chairman & Managing Director Rajeev Juneja said. Shares of Mankind Pharma on Tuesday ended 0.7 per cent lower at Rs 1,741.10 apiece on the BSE.
The firm worked closely with ManKind Pharma and ran an internal cost reduction program which saved them close to Rs 100 crores
The fresh issue component of the IPO is only Rs 180 crore and the remaining is secondary share sale by promoters and TPG
Juneja also highlighted a 43 per cent YoY increase in Ebitda as a positive outcome of the company's previous initiatives to improve profitability
Stocks to Watch on Wednesday, July 5: LTIMindtree will replace HDFC in the benchmark Nifty50 index, while LIC Housing Finance will likely replace it in the Nifty Financial Services index
The company, which raised Rs 4,330 crore ($528 million) in India's second-largest new share sale this year, has seen its shares jump 57% in almost two months, drawing a rush of buy calls from analysts
The company's stock has surged more than 60 per cent since listing, driving its market value to about $8.5 billion
The benchmark indices registered declines in the previous two trading sessions, which could be a bearish sign, observe analysts
The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) is another major reason for the growth in demand for medicines in smaller towns
Currently, the stock was quoting 40 per cent higher over its issue price of Rs 1,080.
Stocks to watch on June 1, 2023: From Coal India to Mankind Pharma, here are top stocks to watch in Thursday's trading session
Mankind Pharma on Wednesday reported 52 per cent increase in consolidated profit after tax (PAT) at Rs 294 crore for March quarter 2022-23, aided by robust sales. The company had logged a PAT of Rs 193 crore in January-March 2021-22. Revenue from operations rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period, Mankind Pharma said in a statement. In 2022-23, the PAT declined 10 per cent to Rs 1,310 crore from Rs 1,453 crore in the previous year. "The company maintained its strong growth trajectory during the year..our consumer healthcare business has maintained its double-digit growth with dominant brand leadership in its categories," Mankind Pharma Vice Chairman and Managing Director Rajeev Juneja said. Earlier this month, the Income Tax Department conducted raids on the premises of the company over allegations of tax evasion.
CLOSING BELL ON MAY 30, 2023: The NSE Nifty 50 gained 35 points at 18,634; while the Bank Nifty hit a fresh all-time high at 44,499.
Analysts say retail investors' enthusiasm fizzled out post the muted listing of a majority of public offers in CY22
From a low of Rs 1,356 apiece, the stock vaulted 6 per cent to hit an intra-day high of Rs 1,439
Stocks to watch today: Mankind Pharma has confirmed that the Income Tax Department conducted a search at some of the premises/ plants related to the Company and some of its subsidiaries
India's Income Tax Department is conducting searches at Mankind Pharma Ltd's office in New Delhi, a government source told Reuters on Thursday, days after the condom maker's successful public listing
The stellar listing day performance comes even as retail investors gave the Rs 4,326-crore IPO - the largest in more than a year-a miss
Mankind's deal marks the return of mid-to-large-sized debuts in India